Download PDF
Dtsch Med Wochenschr 2016; 141(13): 927-932
DOI: 10.1055/s-0042-103978
Dossier
Nachsorge nach Organtransplantation
© Georg Thieme Verlag KG Stuttgart · New York

Langzeitbetreuung nach Organtransplantation

Long-term-management of organ transplant recipients
Christin Bürger
1   Klinik für Transplantationsmedizin, Universitätsklinikum Münster
,
Martina Schmidt
1   Klinik für Transplantationsmedizin, Universitätsklinikum Münster
,
Miriam Maschmeier
1   Klinik für Transplantationsmedizin, Universitätsklinikum Münster
,
Jaqueline Stella
1   Klinik für Transplantationsmedizin, Universitätsklinikum Münster
,
Anna Hüsing
1   Klinik für Transplantationsmedizin, Universitätsklinikum Münster
,
Christian Wilms
1   Klinik für Transplantationsmedizin, Universitätsklinikum Münster
,
Hartmut Hans-Jürgen Schmidt
1   Klinik für Transplantationsmedizin, Universitätsklinikum Münster
,
Iyad Kabar
1   Klinik für Transplantationsmedizin, Universitätsklinikum Münster
› Author Affiliations
Further Information

Publication History

Publication Date:
30 June 2016 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Überlebensraten nach Organtransplantation sind aufgrund von Fortschritten in der immunsuppressiven Therapie und Verbesserung der chirurgischen Technik in den letzten Jahrzehnten stetig gestiegen. In der Langzeitnachsorge nach Organtransplantation sind sowohl die Diagnose und Behandlung Transplantat-assoziierter Komplikationen als auch die Berücksichtigung von Begleiterkrankungen und Nebenwirkungen der Immunsuppression relevant, um Folgeerkrankungen zu verhindern. Insbesondere kardiovaskuläre und metabolische Erkrankungen sowie Tumorerkrankungen spielen im Langzeitverlauf eine große Rolle. Daher sind Screening-Untersuchungen auf eben diese häufigen Komplikationen ein zentraler Bestandteil der Langzeitnachsorge.

Abstract

Due to advances in immunosuppressive therapy and surgical techniques, survival rates after solid organ transplantation have constantly improved over the last decades. In long-term care after transplantation, physicians need to focus as much on diagnosis and treatment of allograft-related complications as they should consider comorbidities and evaluate risk-factors and adverse events of immunosuppressive agents to prevent secondary diseases. In particular, cardiovascular and metabolic diseases, malignancy and infection play a major role in long-term survival. Therefore, screening of organ transplant recipients in regard to these complications and adverse events is a crucial part of follow up in these patients.

Schlüsselwörter

Organtransplantation - Langzeitbetreuung - Immunsuppression - Begleiterkrankungen

Keywords

solid-organ-transplantation - long-term-management - immunosuppression - comorbidities
 

  • Literatur

  • 1 Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450-462
    CrossrefPubMedGoogle Scholar
  • 2 Watt KD, Pedersen RA, Kremers WK et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427
    CrossrefPubMedGoogle Scholar
  • 3 Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report 2012. J Heart Lung Transplant 2012; 31: 1052-1064
    CrossrefPubMedGoogle Scholar
  • 4 Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transplant 2005; 11: 1307-1314
    CrossrefPubMedGoogle Scholar
  • 5 Luke RG. Mechanism of cyclosporine-induced hypertension. Am J Hypertens 1991; 4: 468-471
    CrossrefPubMedGoogle Scholar
  • 6 De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346
    CrossrefPubMedGoogle Scholar
  • 7 Eidelman BH, Abu-Elmagd K, Wilson J et al. Neurologic complications of FK 506. Transplant Proceed 1991; 23: 3175-3178
    PubMedGoogle Scholar
  • 8 Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004; 18: 485-492
    CrossrefPubMedGoogle Scholar
  • 9 Brattstrom C, Wilczek H, Tyden G et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272-1274
    CrossrefPubMedGoogle Scholar
  • 10 Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-1042
    CrossrefPubMedGoogle Scholar
  • 11 Dean PG, Lund WJ, Larson TS et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555-1561
    CrossrefPubMedGoogle Scholar
  • 12 Agraharkar ML, Cinclair RD, Kuo YF et al. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Intern 2004; 66: 383-389
    CrossrefPubMedGoogle Scholar
  • 13 Grulich AE, van Leeuwen MT, Falster MO et al. Incidence of cancers in people with HIV / AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67
    CrossrefPubMedGoogle Scholar
  • 14 Engels EA, Pfeiffer RM, Fraumeni Jr JF et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891-1901
    CrossrefPubMedGoogle Scholar
  • 15 Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-186
    CrossrefPubMedGoogle Scholar
  • 16 Webb MC, Compton F, Andrews PA et al. Skin tumours posttransplantation: a retrospective analysis of 28 years‘ experience at a single centre. Transplant Proceed 1997; 29: 828-830
    CrossrefPubMedGoogle Scholar
  • 17 Euvrard S, Kanitakis J, Pouteil-Noble C et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proceed 1995; 27: 1767-1768
    PubMedGoogle Scholar
  • 18 Bouwes Bavinck JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996; 61: 715-721
    PubMedGoogle Scholar
  • 19 Bavinck JN, De Boer A, Vermeer BJ et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Brit J Dermatol 1993; 129: 242-249
    CrossrefPubMedGoogle Scholar
  • 20 Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691
    CrossrefPubMedGoogle Scholar
  • 21 Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?. Transplantation 2003; 76: 984-988
    CrossrefPubMedGoogle Scholar
  • 22 Baccarani U, Adani GL, Serraino D et al. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proceed 2009; 41: 1303-1305
    CrossrefPubMedGoogle Scholar
  • 23 Verran DJ, Mulhearn MH, Dilworth PJ et al. Nature and outcomes of the increased incidence of colorectal malignancy after liver transplantation in Australasia. Med J Austral 2013; 199: 610-612
    PubMedGoogle Scholar
  • 24 Geissler EK, Schnitzbauer AA, Zulke C et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016; 100: 116-125
    CrossrefPubMedGoogle Scholar
  • 25 Rubin RH, Kemmerly SA, Conti D et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transplant Infect Dis 2000; 2: 112-117
    CrossrefPubMedGoogle Scholar
  • 26 Patel R, Portela D, Badley AD et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62: 926-934
    CrossrefPubMedGoogle Scholar
  • 27 Green H, Paul M, Vidal L et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. The Cochrane database of systematic reviews 2007; DOI: 10.1002/14651858.CD005590.pub2. Cd005590
    PubMedGoogle Scholar
  • 28 Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751
    CrossrefPubMedGoogle Scholar
  • 29 Bronsther O, Manez R, Kusne S et al. Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation. Transplant Proceed 1995; 27: 1206-1207
    PubMedGoogle Scholar
  • 30 Timms JM, Bell A, Flavell JR et al. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin‘s lymphoma. Lancet 2003; 361: 217-223
    CrossrefPubMedGoogle Scholar
  • 31 Blumberg EA, Albano C, Pruett T et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295-302
    CrossrefPubMedGoogle Scholar
  • 32 Avery RK. Immunizations in adult immunocompromised patients: which to use and which to avoid. Cleve Clin J Med 2001; 68: 337-348
    CrossrefPubMedGoogle Scholar
  • 33 Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287-291
    CrossrefPubMedGoogle Scholar
  • 34 Danziger-Isakov L, Kumar D. Vaccination in solid organ transplantation. Am J Transplant 2013; 13: 311-317
    CrossrefPubMedGoogle Scholar
  • 35 Taler SJ, Textor SC, Canzanello VJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588-1592
    CrossrefPubMedGoogle Scholar
  • 36 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH / ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Europ Heart J 2013; 34: 2159-2219
    CrossrefPubMedGoogle Scholar
  • 37 Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001; 71: 42-51
    PubMedGoogle Scholar
  • 38 Van Riemsdijk IC, Mulder PG, de Fijter JW et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation 2000; 70: 122-126
    PubMedGoogle Scholar
  • 39 Midtvedt K, Hartmann A, Foss A et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72: 1787-1792
    CrossrefPubMedGoogle Scholar
  • 40 Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185
    CrossrefPubMedGoogle Scholar
  • 41 Hernandez D, Lacalzada J, Salido E et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Intern 2000; 58: 889-897
    CrossrefPubMedGoogle Scholar
  • 42 Barnas U, Schmidt A, Haas M et al. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996; 11: 1822-1824
    CrossrefPubMedGoogle Scholar
  • 43 Philipp T, Martinez F, Geiger H et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010; 25: 967-976
    CrossrefPubMedGoogle Scholar
  • 44 Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185
    CrossrefPubMedGoogle Scholar
  • 45 Hjelmesaeth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-983
    CrossrefPubMedGoogle Scholar
  • 46 Martinez-Castelao A, Hernandez MD, Pascual J et al. Detection and treatment of post kidney transplant hyperglycemia: a Spanish multicenter cross-sectional study. Transplant Proceed 2005; 37: 3813-3816
    CrossrefPubMedGoogle Scholar
  • 47 Heisel O, Heisel R, Balshaw R et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4: 583-595
    CrossrefPubMedGoogle Scholar
  • 48 Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514
    CrossrefPubMedGoogle Scholar
  • 49 Johnston O, Rose CL, Webster AC et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418
    CrossrefPubMedGoogle Scholar
  • 50 Morard I, Dumortier J, Spahr L et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transplant 2007; 13: 658-664
    CrossrefPubMedGoogle Scholar
  • 51 Martin JE, Cavanaugh TM, Trumbull L et al. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transplant 2008; 22: 113-119
    PubMedGoogle Scholar
  • 52 Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63: 367-378
    CrossrefPubMedGoogle Scholar
  • 53 Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031
    CrossrefPubMedGoogle Scholar
  • 54 Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73-81
    CrossrefPubMedGoogle Scholar
  • 55 Westenfeld R, Schlieper G, Woltje M et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease. Nephrol Dial Transplant 2011; 26: 4115-4123
    CrossrefPubMedGoogle Scholar
  • 56 Millonig G, Graziadei IW, Eichler D et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transplant 2005; 11: 960-966
    CrossrefPubMedGoogle Scholar
  • 57 Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940
    CrossrefPubMedGoogle Scholar
  • 58 Porayko MK, Textor SC, Krom RA et al. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. Transplant Proceed 1993; 25: 665-668
    PubMedGoogle Scholar
  • 59 Cantarovich M, Tchervenkov J, Paraskevas S et al. Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation 2011; 92: 1358-1363
    CrossrefPubMedGoogle Scholar
  • 60 Mayr M. Management nach Transplantation. Ther Umsch 2005; 62: 487-501
    CrossrefPubMedGoogle Scholar